Fig. 4
From: CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation

CLDN6 modulates the localization of palmitoylated RAS via VPS4A. A-D The localization of RAS (red) in BC cells with CLDN6 overexpression(A), palmitic acid treatment (B), SREBP1 overexpression (C), and 2BP treatment (D-E). Scale bar, 20 μm. F The interaction between VPS4A and HRAS. G, H The impact of CLDN6 overexpression on palmitoylation (G) and localization (H) of HRAS (green) in BC cells. Scale bar, 20 μm. I, J The regulatory impact of CLDN6 overexpression on the binding between HRAS and VPS4A (I) and the colocalization of HRAS (red) and VPS4A (green) (J). Scale bar, 20 μm. K-L The alteration of the binding between HRAS and VPS4A (K) and the colocalization of HRAS (red) with VPS4A (green) (L) in SREBP1-overexpressing BC cells induced by 2BP treatment. Scale bar, 20 μm